GLOW
GLOW is a combination sold as one vial, pairing three peptides: GHK-Cu, BPC-157 and TB-500. It is studied for skin quality, tissue repair and recovery, though no trial has tested the three together in people.
This is a combination sold as one vial. It has not been studied as a single substance, so what is known is what is known about each part, linked above. Sources that report a dose for the blend report it for that mixture, not for any component on its own.
At a glance
- BPC-157 / GHK-Cu / TB-500, BPC-157 10mg / GHK-Cu 50mg / TB-500 10mg 70mg
- Recovery & tissue repair
- subcutaneous
- Not yet audited here; the reference library calls it emerging
- Sources differ. All 2 sources
- 70 mg in 3 mL
How much to draw
Full calculator →The reference does not report a single injectable amount for GLOW, so the amount is yours to enter. The arithmetic is the same for any vial. How to reconstitute a vial.
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for GLOW or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| Pre-blend: 0.10 mL (10 units) daily = ~2.33 mg total blend (~1.67 mg GHK-Cu, ~0.33 mg TB-500, ~0.33 mg BPC-157). Separate vials: BPC-157 250-500 mcg/day; TB-500 2.5-5 mg per injection 2x/week (loading), 2 mg per injection (maintenance); GHK-Cu 1-2 mg/day (loading), 1 mg/day (maintenance). | Once daily (pre-blend); separate vials: BPC-157 daily, TB-500 twice weekly, GHK-Cu dailyStandard: 4-6 weeks on, 2-4 weeks off; Extended: 8-12 weeks on, 4-8 weeks off; Skin-focused blend: 4 weeks on, 2-4 weeks off. GHK-Cu copper cycling typically governs cycle length: 30-60 days on, equal time off. | subcutaneous | peptidedosingprotocols.comWhat it saysHide[Source: peptidedosingprotocols.com] |
| 10 units (0.10 mL) daily, approximately 2.33 mg total blend. | not stated | not stated | Peptide Dosing Protocols stack |
- Once daily (pre-blend); separate vials: BPC-157 daily, TB-500 twice weekly, GHK-Cu dailyStandard: 4-6 weeks on, 2-4 weeks off; Extended: 8-12 weeks on, 4-8 weeks off; Skin-focused blend: 4 weeks on, 2-4 weeks off. GHK-Cu copper cycling typically governs cycle length: 30-60 days on, equal time off.
- subcutaneous
- peptidedosingprotocols.com
What it saysHide
[Source: peptidedosingprotocols.com]
- not stated
- not stated
- Peptide Dosing Protocols stack
- Pre-blend (70 mg vial): Add 3.0 mL bacteriostatic water → ~23.3 mg/mL total blend; standard daily dose is 0.10 mL (10 units) = ~2.33 mg total. Separate vials, BPC-157 5 mg vial: add 2 mL BAC water → 2,500 mcg/mL; BPC-157 10 mg vial: add 2 mL BAC water → 5,000 mcg/mL. TB-500 5 mg vial: add 1 mL BAC water → 5 mg/mL; TB-500 10 mg vial: add 2 mL BAC water → 5 mg/mL. GHK-Cu 50 mg vial: add 5 mL BAC water → 10 mg/mL; GHK-Cu 100 mg vial: add 10 mL BAC water → 10 mg/mL. Standard steps: wipe stopper with alcohol swab and let dry; draw planned BAC water volume; aim water at inside of glass wall, not directly onto powder; let water flow slowly down vial wall; roll gently 30-60 seconds until dissolved (do not shake); inspect for clarity (GHK-Cu may show slight blue/green tint from copper; BPC-157 and TB-500 should be clear); label with reconstitution date and store at 2-8 °C (35.6-46.4 °F). TB-500 is the limiting reconstitution-stability window, most workflows use the reconstituted blend within 1-2 weeks.
- Add 3.0 mL bacteriostatic water to reconstitute.
We have not published an audit on GLOW. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
How it is thought to work
Each part is studied for a different stage of repair. BPC-157, a 15-amino-acid peptide first isolated from gastric juice, has been linked in animals to new blood vessels at injury sites; TB-500, a synthetic piece of Thymosin Beta-4, acts on actin, the protein that gives cells their shape and helps them move, so repair cells can travel where they are needed; and GHK-Cu, a copper-bound tripeptide found in human plasma, has been studied for collagen and elastin production and for matrix remodelling. Each is reported to calm inflammation through a different pathway in preclinical models, which is the interest in combining them. There is no published human trial of the three together.
Combines copper peptide (GHK-Cu) with repair peptides (BPC-157, TB-500); studied for skin, tissue repair, and recovery.
Reported side effects
Seen in studies: BPC-157 has not produced a lethal dose in animal toxicity work, intravenous thymosin beta-4 went through Phase I and Phase II trials with no serious adverse events reported in the published groups, and GHK-Cu has decades of use in topical and cosmetic products.
Reported by users: irritation where it is injected, with redness and mild swelling that usually settles within minutes to hours; short-term tiredness in the first 1-2 weeks of TB-500 loading; occasional mild, passing headache; and a slight metallic or warm feeling at the site from GHK-Cu.
Not ruled out: no clinical trial has tested the combination. BPC-157 and TB-500 both promote new blood-vessel growth, so that signal overlaps; copper from GHK-Cu may build up over time, which is why sources describe cycling 30-60 days on and the same time off; and each extra compound is another chance of contamination or an under-dosed vial.
Who should avoid it
People with active cancer or a vascular disorder: BPC-157 and TB-500 both promote new blood-vessel growth, and that signal overlaps in the blend.
Competitive athletes: BPC-157 and TB-500 are prohibited by WADA.
Anyone expecting an approved medicine: none of the three compounds is FDA-approved for injectable human use.
What gets monitored
COA (Certificate of Analysis) verification from suppliers is named; an at-home blood test (SiPhox Health) is listed as a supply item. The page advises reassessing if injection-site reactions worsen, fatigue persists past the loading phase, or any unusual symptoms occur, but no specific lab panels are named. (reported by peptidedosingprotocols.com)
Common questions
What is GLOW peptide?
GLOW is a research blend of three compounds, BPC-157, TB-500 and GHK-Cu, usually sold pre-blended at a 5:1:1 ratio that makes it GHK-Cu dominant. It pairs the soft-tissue repair research around BPC-157 and TB-500 with the collagen and matrix work around GHK-Cu.
What is in the GLOW peptide blend?
Most pre-blended products contain 50 mg GHK-Cu, 10 mg TB-500 and 10 mg BPC-157 in a single 70 mg vial. That is the 5:1:1 ratio described above.
What is GLOW peptide researched for?
Compound-level research links the combination to soft-tissue repair, collagen and skin-quality remodelling from GHK-Cu, overlapping anti-inflammatory pathways, and more organised matrix formation. There is no published human trial of the three compounds together.
How is GLOW peptide commonly dosed in research planning?
Reported amounts and schedules for GLOW differ by source, and peppersite does not recommend one. Each reported figure is listed in the dosing rows on this page, next to the source that reports it.
How is the GLOW peptide blend reconstituted?
That depends on the vial size and how much water is added. The calculator on this page works out the draw for any combination, and the reconstitution guide covers the steps.
How long are typical GLOW cycles?
Community protocols described in the reference run 4-6 weeks on with 2-4 weeks off. The schedule is usually set by GHK-Cu copper cycling, reported as 30-60 days on with an equal time off.
What is the difference between GLOW and Wolverine peptide?
Wolverine is BPC-157 and TB-500 only, so it is repair-focused. GLOW adds GHK-Cu, which brings collagen and skin-quality remodelling into the blend, making it more complex and more expensive.
What are the GLOW peptide side effects?
The effects reported most often are mild injection-site irritation, short-term tiredness during TB-500 loading, and occasional headache. The main blend-specific consideration is the overlapping blood-vessel-growth signal from BPC-157 and TB-500, which is why people with active cancer or vascular disorders are told to avoid these compounds.
Sources
The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.
BPC-157 (Body Protection Compound 157) is a lab-made chain of 15 amino acids based on a sequence first found in human gastric juice. It is mostly studied in animal models of tendon, ligament, gut and blood-vessel injury, and human evidence is limited to three small pilots.
GHK-Cu, or copper tripeptide-1, is a natural peptide of three amino acids bound to a copper ion, found in human blood plasma. It is studied for skin, hair and wound repair, mostly in cells and animals, with the strongest human evidence for topical use.
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small lab-made molecule, not a true peptide, though it is often sold alongside research peptides. It is studied for shrinking fat cells and raising NAD+ levels, and all evidence so far comes from cell and rodent studies, with no published human trial.
Cerluten is an oral peptide bioregulator referenced for nervous system support. Its proposed action, tissue-specific peptide bioregulation, is described as theoretical.
CJC-1295 with DAC is a lab-made 30-amino-acid copy of growth hormone-releasing hormone, altered so it attaches to albumin, a protein in the blood. It was studied in early human trials for its effect on growth hormone and IGF-1 levels.
This is a combination research blend sold as one vial: CJC-1295 without DAC, a copy of growth hormone-releasing hormone, plus Ipamorelin, a short peptide that acts on the ghrelin receptor. It is studied as a GHRH and GHRP pairing in growth-hormone research.